Zedge (ZDGE) Reaches $1.85 1 Year Low; Sunesis Pharmaceuticals (SNSS) Sellers Decreased By 4.92% Their Shorts

August 7, 2017 - By Maria Brooks

The stock of Zedge Inc (NYSEMKT:ZDGE) hit a new 52-week low and has $1.72 target or 7.00% below today’s $1.85 share price. The 7 months bearish chart indicates high risk for the $17.85M company. The 1-year low was reported on Aug, 7 by Barchart.com. If the $1.72 price target is reached, the company will be worth $1.25 million less. About 1,399 shares traded. Zedge Inc (NYSEMKT:ZDGE) has 0.00% since August 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS) had a decrease of 4.92% in short interest. SNSS’s SI was 255,000 shares in August as released by FINRA. Its down 4.92% from 268,200 shares previously. With 44,400 avg volume, 6 days are for Sunesis Pharmaceuticals Incorporated (NASDAQ:SNSS)’s short sellers to cover SNSS’s short positions. The SI to Sunesis Pharmaceuticals Incorporated’s float is 2.1%. About 1,044 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since August 7, 2016 and is uptrending. It has underperformed by 8.37% the S&P500.

Among 4 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Sunesis Pharmaceuticals had 6 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by TH Capital on Friday, July 24 to “Sell”. Wells Fargo upgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Friday, July 29 to “Outperform” rating. The company was maintained on Thursday, July 27 by Cantor Fitzgerald. The firm has “Hold” rating given on Tuesday, July 18 by Cantor Fitzgerald. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) earned “Hold” rating by Cantor Fitzgerald on Friday, July 24. On Friday, July 24 the stock rating was downgraded by Cowen & Co to “Market Perform”.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $58.55 million. The Firm focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. It currently has negative earnings. The Firm offers QINPREZO , which is a product candidate for the treatment of acute myeloid leukemia (AML).

Zedge, Inc. is a provider of content distribution platforms, centered on self-expression, enabling both creators looking to promote their content and clients utilizing such content to express their identity, feelings, tastes and interests. The company has market cap of $17.85 million. The Company’s platform enables clients to personalize their mobile devices with free, ringtones, wallpapers, home screen application icons and notification sounds. It currently has negative earnings. The users primarily access the Company’s content through its smartphone application, called Zedge.